作为抗体介导的自身免疫脑炎的快速作用的补充疗法,efgartigimod
Zhuajin Bi1, Wenzhong Kang1, Ruihan Liu2
1Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
European journal of neurology
|August 4, 2025
概括
与IVMP结合的efgartigimod与IVMP单独相比,在自身免疫性脑炎 (AE) 中显示出更快的改善. 这种组合疗法对抗体介导的AE是安全有效的,需要进一步研究.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 自身免疫性脑炎 (AE) 在神经学中是一个重大挑战,需要有效和安全的治疗策略.
- 目前对AE的治疗需要优化,以改善患者的治疗结果.
研究的目的:
- 为了比较静脉注射甲基prednisolone (IVMP) 加efgartigimod (IPE) 与IVMP单独和IVMP加免疫球蛋白 (IPI) 作为抗体介导AE的初始治疗的疗效和安全性.
- 通过验证的临床尺度来评估治疗反应,并评估安全概况.
主要方法:
- 采用了一种回顾性,单中心,横截面的研究设计.
- 倾向分数匹配 (PSM) 用于控制治疗组之间的混变量.
- 用临床评估尺度 (CASE) 和修改的兰金尺度 (mRS) 在多个时间点评估临床结果,最长为12周.
主要成果:
- 与IVMP组相比,IPE组在2周后在CASE和mRS得分上显示出显著更大的改善.
- 与IVMP组相比,IPE组中更高比例的患者获得了良好的结果 (mRS ≤2) (75.0%对20.0%).
- 在12周内,IPE和IPI组之间没有观察到治疗反应的显著差异;efgartigimod表现出良好的安全性,只有轻微的,短暂的副作用.
结论:
- 添加到IVMP时的efgartigimod在抗体阳性AE患者中显示出快速的疗效和良好的安全性.
- 这些发现支持efgartigimod作为现有AE治疗方案的有价值补充的潜力.
- 建议进行更大规模的临床试验,以进一步验证这些有希望的结果.
相关概念视频
01:20Antiepileptic Drugs: Potassium Channel Activators
278
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
278
01:14Antiepileptic Drugs: Glutamate Antagonists
516
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
516
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
650
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
650
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
450
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
450
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
271
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
271
01:20Myasthenia Gravis: Overview and Treatment
1.9K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.9K